Technological and Biological Characterization of Idebenone-Loaded Solid Lipid Nanoparticles Prepared by a Modified Solvent Injection Technique

Stancampiano, Annalisa H.S.; Acquaviva, Rosaria; Campisi, A.; Vanella, Luca; Ventura, Cinzia Anna; Puglisi, Giovanni; Pignatello, Rosario

doi:10.1166/jbn.2006.033

Cited by 16 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The core remains in the solid state at room and body temperature and is coated with amphiphilic surfactants that form the outer shell . Many solid lipids, such as stearic acid, palmitic acid, glycerol behenate (Compritol 888 ATO), and glyceryl monostearate have been used in preparing SLNs. Similarly, various surfactants, such as poloxamer 188, 182, 407, 908, tween 20, 80, and solutol HS 15 have been reported to stabilize the SLN formulation.…”

Section: Nanoengineered Antibiotic Delivery Systemsmentioning

confidence: 99%

Nanoengineered Drug Delivery Systems for Enhancing Antibiotic Therapy

Kalhapure

Suleman

Mocktar

et al. 2015

Journal of Pharmaceutical Sciences

173

105

View full text Add to dashboard Cite

Section: Nanoengineered Antibiotic Delivery Systemsmentioning

confidence: 99%

Nanoengineered Drug Delivery Systems for Enhancing Antibiotic Therapy

Kalhapure

Suleman

Mocktar

et al. 2015

Journal of Pharmaceutical Sciences

173

105

View full text Add to dashboard Cite

“…We have recently proposed a method for producing LN that intrinsically encompasses a number of positive aspects for an ophthalmic or a parenteral formulation. The Quasi-Emulsion Solvent Diffusion method (QESD), detailed in the Experimental section, was originally proposed for the preparation of polymeric nanosystems [24][25][26], but has been later exploited for the formulation of SLN [27][28][29]. It allows to work under operative and formulation conditions compatible with the requirements for an ophthalmic dosage form.…”

Section: Lipid Nanoparticles (Ln) For Ocular Applicationmentioning

confidence: 99%

Optimization and Validation of a New Method for the Production of Lipid Nanoparticles for Ophthalmic Application

Pignatello

Leonardi²,

Cupri³

2014

Int J Med Nano Res

View full text Add to dashboard Cite

of a topically applied formulation with the corneal surface produces an inadequate bioavailability at the level of the target sites, with the necessity of repeated instillations of the formulation [2,3]. The pharmaceutical market is thus monitoring the potentiality of novel therapeutic strategies for pathological situations such as diabetic retinopathy, macular degeneration, uveitis, vascular diseases of the retina, responsible for millions cases of visual impairment or blindness in the world [4,5]. However, conventional dosage forms, like eye-drops or semisolid gels and ointments, are not sufficiently valid for delivering innovative active agents, such as peptide drugs, monoclonal antibodies or gene material. This prompted to exploit the applicability to the ocular field of innovative drug delivery systems (DDS), in most cases originally developed for other routes of application, such as parenteral or oral ones. Depending on their composition, cSLN systems with a mean size around 170-250 nm, a good size distribution profile, and a net positive charge (+30/+50 mV) were produced by the QESD technique. Only highly biocompatible, ICH-class 3 solvents, such as ethanol and acetone, were used. Most nanocarriers showed a good physical stability upon storage and could be produced respecting some formulation requirements, such as pH close to neutrality and an osmolarity compatible with the eye surface.

show abstract

“…lipids matrix used is solid at room temperature and also at body temperature which are stabilized by surfactants (Gasco, 1993). For preparation of SLNs high-pressure homogenization, microemulsions by the phase-inversion temperature (PIT) and more efficient solvent injection techniques are used through the point of attainment in nanoscale particle size (Stancampiano et al, 2006;Montenegro et al, 2011). Factorial design approach was generally implemented for the determination of optimum levels of formulation and process variables in design and development of SLNs (Carbone et al, 2012b).…”

Section: Introductionmentioning

confidence: 99%

“…In one of the biological study, it has been reported that IDE-loaded SLNs were more effective in inhibiting 2,2 0 -azobis-2-amidinopropane dihydrochloride (APPH) induced ROS production in primary cultures of newborn rat astrocytes compared to the free drug (Carbone et al, 2012a;Stancampiano et al, 2006). Though there are reports about lipid nanocarriers and the various formulations of IDE for delivery of the drug for the topical, cosmetic, parenteral and oral applications, existing in the literature but there is none of the reports which discloses the IDE loaded lipid-based nanostructured carriers in the form of NLCs considered as most advanced generation of lipid nanoparticles as oral drug delivery system for brain to treat the neurodegenerative disorders.…”

Section: Introductionmentioning

confidence: 99%

Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain

Salunkhe¹,

Bhatia²,

Bhatia

2014

Drug Delivery

View full text Add to dashboard Cite

Context & Objective: The aim of present investigation was to formulate and develop lipid-based nanostructured carriers (NLCs) containing Idebenone (IDE) for delivery to brain. Attempts have been made to evaluate IDE NLCs for its pharmacokinetic and pharmacodynamic profile through the objective of enhancement in bioavailability and effectivity of drug. Methods: Nanoprecipitation technique was used for development of drug loaded NLCs. The components solid lipid Precirol ATO 5, oil Miglyol 840, surfactants Tween 80 and Labrasol have been screened out for formulation development by consideration of preformulation parameters including solubility, Required Hydrophilic lipophilic balance (HLB) of lipids and stability study. Developed IDE NLCs were subjected for particle size, zeta potential, entrapment efficiency (%EE), crystallographic investigation, transmission electron microscopy, in vitro drug release, pharmacokinetics, in vivo and stability study. Results: Formulation under investigation has particle size 174.1 ± 2.6 nm, zeta potential À18.65 ± 1.13 mV and% EE 90.68 ± 2.90. Crystallographic studies exemplified for partial amorphization of IDE by molecularly dispersion within lipid crust. IDE NLCs showed drug release 93.56 ± 0.39% at end of 24 h by following Higuchi model which necessitates for appropriate drug delivery with enhancement in bioavailability of drug by 4.6-fold in plasma and 2.8-fold in brain over plain drug loaded aqueous dispersions. In vivo studies revealed that effect of drug was enhanced by prepared lipid nanocarriers. Conclusions: IDE lipid-based nanostructured carriers could have potential for efficient drug delivery to brain with enhancement in bioavailability of drug over the conventional formulations.

show abstract

Technological and Biological Characterization of Idebenone-Loaded Solid Lipid Nanoparticles Prepared by a Modified Solvent Injection Technique

Cited by 16 publications

References 0 publications

Nanoengineered Drug Delivery Systems for Enhancing Antibiotic Therapy

Nanoengineered Drug Delivery Systems for Enhancing Antibiotic Therapy

Optimization and Validation of a New Method for the Production of Lipid Nanoparticles for Ophthalmic Application

Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain

Contact Info

Product

Resources

About